
Sequoia China Capital and Highlight Capital co-led the GNI Group-backed cancer drug developer's series A round.
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
FujiFilm-backed genetic disorder drug developer EdiGene has secured $14.3m from investors including SBI Investment, SMBC Capital and Mizuho Capital.
Novo and Sanofi Ventures returned to reinvest in Inozyme Pharma as it looks to advance its lead mineralisation disorder drug towards the clinic.
Varian Medical Systems co-led the series B round, which will fund the development of ABK Biomedical's embolic therapies.
Perspectives on sustainability and wellbeing are changing in response to health and environmental challenges, offering an opportunity to university-linked businesses.
SoftBank has tapped three executives to help run its $5bn Latin America-focused fund, with Paulo Passoni and Shu Nyatta to work alongside managing partner André Maciel.
The cosmetic surgery booking and reviews platform, which counts Tencent among its investors, has filed to go public in the US.
Lundbeckfonden Ventures-backed Trevi has filed for an $86.2m IPO to fund clinical trials for pruritus-focused drug treatments.
The insurance provider has teamed with the city of Wuhan to form a healthcare fund sized at approximately $3bn, with LPs including WeDoctor and Jointown Pharmaceutical.